MedTrace Logo

Woodsmoke Exposure, Influenza Infection, and Nasal Immunity

NCT06841913 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2026-04-30

No results posted yet for this study

Summary

This study will investigate the effects of woodsmoke (WS) exposure on human nasal mucosal immune responses to viral infection. The study tests the hypotheses that WS exposure modifies biomarkers of nasal mucosal immune function, increases in Live Attenuated Influenza Virus (LAIV) -induced nasal symptoms, and reduces mucosal antibody production.

Conditions

Interventions

BIOLOGICAL

LAIV nasal vaccine is chosen as a model viral infection

Inoculation with LAIV

OTHER

Wood smoke

Wood smoke exposure concentrations at 500 ug/m3 for two hours.

BIOLOGICAL

Placebo for LAIV nasal vaccine is chosen as a model viral infection

Placebo for LAIV inoculation. Nasal administration of normal saline.

OTHER

Placebo for Wood Smoke (clean Air Exposure)

Clean Air Exposure for 2 hours

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Institute of Environmental Health Sciences (NIEHS)

    collaborator NIH

  • University of North Carolina, Chapel Hill

    lead OTHER

Principal Investigators

  • Meghan Rebuli, PhD · UNC

  • Terry Noah, MD · UNC

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-09-26
Primary Completion
2028-12-31
Completion
2028-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06841913 on ClinicalTrials.gov